17-Deacetylnorgestimate

17-Deacetylnorgestimate Uses, Dosage, Side Effects, Food Interaction and all others data.

17-Deacetylnorgestimate is a drug used in contraception. 17-Deacetylnorgestimate is the active progestin responsible for the progestational activity that occurs in women after application of ORTHO EVRA patch.

17-Deacetylnorgestimate is used for contraception and menopausal hormonal therapy transdermally or in combination with ethinyl estradiol as a vaginal ring. 17-Deacetylnorgestimate, in combination with ethinyl estradiol inhibits ovulation by suppressing gonadotropins.

17-Deacetylnorgestimate
Uses
Dosage
Side Effect
Precautions
Interactions
Uses during Pregnancy
Uses during Breastfeeding
Accute Overdose
Food Interaction
Half Life
Volume of Distribution
Clearance
Interaction With other Medicine
Contradiction
Storage

Trade Name	17-Deacetylnorgestimate
Generic	Norelgestromin
Norelgestromin Other Names	17-Deacetylnorgestimate, 17-Deacylnorgestimate, D-Norgestrel 3-oxime, Deacetylnorgestimate, Levonorgestrel 3-oxime, Levonorgestrel oxime, Norelgestromin, Norelgestromina, Norplant 3-oxime
Type
Formula	C₂₁H₂₉NO₂
Weight	Average: 327.468 Monoisotopic: 327.219829178
Groups	Approved, Investigational
Therapeutic Class
Manufacturer
Available Country
Last Updated:	September 19, 2023 at 7:00 am

Uses

17-Deacetylnorgestimate is a progestin used for the prevention of pregnancy in women who elect to use a transdermal patch as a method of contraception.

17-Deacetylnorgestimate is used for contraception and menopausal hormonal therapy. 17-Deacetylnorgestimate may potentially be used in breast cancer treatment due to its inhibitory effect on estrone sulfatase . They convert sulfated steroid precursors to estrogen during pregnancy.

17-Deacetylnorgestimate is also used to associated treatment for these conditions: Polycystic Ovarian Syndrome, Transdermal contraception therapy

How 17-Deacetylnorgestimate works

17-Deacetylnorgestimate inhibits estrone sulfatase, which converts sulfated steroid precursors to estrogen during pregnancy. Norgelgestromin/ethinylestradiol suppresses follicular development, induces changes to the endometrium, which decreases chances of implantation and thickens the cervical mucus, impeding sperm swimming into the uterus. It also has similar agonisting binding affinities as its parent compound, Norgestimate, for progesterone and estrogen receptors.